GlassScriptPhysician profile
Pranjalkumar H Patel
NPI 1225233133
$18,174.05
in general payments reported to CMS, 2019-2025
67 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,964 · 2020: $2,871 · 2021: $3,008 · 2022: $2,675 · 2023: $2,416 · 2024: $2,197 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,656.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,867.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,388.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,136.85 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $995.40 | 2019-2023 | |
| Glaxosmithkline, LLC. | $994.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $895.17 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $780.90 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $687.07 | 2019-2024 | Zoryve |
| Pfizer INC. | $612.42 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $587.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $587.63 | 2019-2024 | Xarelto |
| Amgen INC. | $576.21 | 2019-2025 | Evenity, Otezla, Repatha |
| Esperion Therapeutics, INC. | $473.63 | 2020-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $396.69 | 2023-2025 | Gemtesa |
| Abbvie INC. | $316.39 | 2021-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranjalkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.